The results indicated that patients with higher CLCF1 expression achieved worse OS prognosis in LGG and Pan-glioma in the TCGA cohort (Supplementary Figures S1C–E), and in the CGGA cohort, high CLCF1 subgroup achieved worse OS prognosis in LGG, GBM, and Pan-glioma (Figures 2C –E). This evidence concerns the gene CLCF1 and central nervous system cancer.